Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial.

ABSTRACT:

Background and objectives

Lanthanum carbonate (FOSRENOL, Shire Pharmaceuticals) is an effective noncalcium, nonresin phosphate binder for the control of hyperphosphatemia in chronic kidney disease (CKD) stage 5 patients undergoing dialysis.

Design, setting, participants and measurements

A Phase 2, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of lanthanum carbonate in CKD stage 3 and 4 patients. Of 281 patients screened, 121 were randomized (2:1) to lanthanum carbonate or placebo (80 versus 41). The modified intent-to-treat population included 90 patients (56 versus 34); 71 (43 versus 28) completed the study. After run-in, when any current phosphate binders were discontinued and dietary counseling reinforced, patients with serum phosph

SUBMITTER: Sprague SM 

PROVIDER: S-EPMC2615694 | biostudies-literature | 2009 Jan

REPOSITORIES: biostudies-literature